poly(ADP-ribose) polymerase family member 8Genealiases: ARTD16 · pART16
Q-omics provides the consensus-scored PARP8 profile across patient tissues and cancer cell-line models. PARP8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PARP8 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PARP8 RNA expression shows 19,144 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where PARP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP8 survival associations across molecular data types. PARP8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP8 RNA expression–survival associations across cancer types. High PARP8 expression shows unfavorable associations in UVM and LIHC, but favorable associations in MESO, BLCA, SKCM and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PARP8 RNA expression.
This table summarizes PARP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PARP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP8 shows lower tumor expression in THCA, LUSC and BRCA and higher tumor expression in KIRC, COAD and KIRP. The KIRC box plot shows higher PARP8 RNA expression in tumor versus normal tissue (log2 FC = +0.937, t-test p < 0.001).
This table shows molecular features associated with PARP8 in patient tissues and cancer cell lines. In patient samples, PARP8 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
